| Date | Title (click to view press release) |
| 9/18/2008 |
Cortria Corporation Establishes Scientific Advisory Board to Guide Development of TRIA-662
|
| 9/17/2008 |
Caliber Therapeutics and DSM Biomedical Form Partnership to Advance Novel Drug-Device Convergence Products for Treatment of Atherosclerotic Disease
|
| 9/15/2008 |
Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic with Activity Against Hospital- and Community-Acquired MRSA
|
| 9/10/2008 |
Nomir Medical Presents Positive Onychomycosis Data for its Noveon® Dual Wavelength Device
|
| 9/10/2008 |
Argos Therapeutics Initiates Phase 2 Trial in Renal Cell Carcinoma for its Arcelis™ Personalized Immunotherapy Platform
|
| 9/5/2008 |
NeurAxon’s NXN-188 Demonstrates Pain Relief in Migraine with Aura
|
| 9/4/2008 |
Synageva Biopharma Appoints Sanj K. Patel President and Chief Executive Officer and Opens New Corporate Headquarter
|
| 9/2/2008 |
Idera Pharmaceuticals Announces Milestone Payment Under Asthma and Allergy Collaboration
|
| 8/25/2008 |
Proteostasis Therapeutics Secures a $45 Million Series A Financing to Develop Proteostasis Regulator™ Drugs
|
| 8/11/2008 |
Argos Therapeutics to Discuss Automated Manufacturing Process for its Arcelis™ Personalized Immunotherapy Platform
|
| 8/5/2008 |
Argos Therapeutics’ Arcelis™ Personalized Immunotherapy Platform in HIV Achieves Primary Endpoint in Phase 1 Trial
|
| 8/5/2008 |
Argos Therapeutics and Université de Montréal Present Novel Method to Create Personalized Immunotherapy Treatments that Stimulate HIV-Specific T Cells
|
| 7/16/2008 |
Symphogen and Biovitrum Have Initiated a Novel Treatment Study in Autoimmune Bleeding Disorder (ITP) Patients
|
| 7/14/2008 |
Argos Therapeutics to Discuss Automated Manufacturing Process for Personalized Immunotherapy at IBC Next Generation Vaccines Conference
|
| 7/14/2008 |
Cortria Corporation Announces Appointment of Daniel Grau as CEO & Vice-Chairman and Richard King as Director
|
| 7/9/2008 |
Altus Pharmaceuticals Secures Long-term Growth Hormone Supply for ALTU-238 Clinical Development and Commercialization
|
| 7/8/2008 |
Gemin X Pharmaceuticals Appoints Peter R. Dolan to Board of Directors
|
| 6/30/2008 |
Gemin X Pharmaceuticals, Inc. Closes $38 Million Series C Financing to Advance Lead Cancer Drug, Obatoclax, Into Registration Trials
|
| 6/18/2008 |
Molecular Insight Pharmaceuticals, Inc. Reports Onalta™ Tissue Distribution Data Support Clinical Development Program
|
| 6/18/2008 |
Molecular Insight Pharmaceuticals, Inc. Presents Three Studies on Trofex™ Program for Prostate Cancer Diagnosis and Staging
|
| 6/13/2008 |
Altus Pharmaceuticals Reports Last Patient Visit Of Trizytek™ Phase 3 Efficacy Trial
|
| 6/10/2008 |
Senior Pharmaceutical Executive, Glenn J. Gormley, M.D., Ph.D.,to Lead Gemin X Pharmaceuticals as President and CEO
|
| 6/10/2008 |
Symphogen Enters into Strategic Collaboration with Genentech for Antibody Therapeutics in Infectious Disease
|
| 6/9/2008 |
Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Models of Lung Inflammation and Psoriasis
|
| 6/2/2008 |
TransMolecular Reports Positive Results from Phase 1 Trial of Iodine-TM601 in Metastatic Melanoma
|
| 6/2/2008 |
XANTHUS PRESENTS UPDATED XANAFIDE PHASE 2 DATA SHOWING DURABLE COMPLETE REMISSIONS IN SECONDARY AML
|
| 5/20/2008 |
Dynogen Presents Results of its Positive Phase 2 IBS-d Study with DDP225
|
| 5/20/2008 |
Dynogen Presents Results of its Positive Phase 2a IBS-c Study with DDP733
|
| 5/19/2008 |
Gloucester Pharmaceuticals Announces Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL
|
| 5/19/2008 |
Argos Therapeutics Discusses Novel Solutions for Automated Immunotherapy Manufacturing at ISCT Annual Meeting
|
| 5/19/2008 |
Nomir Medical Initiates Pivotal Trial of its Noveon® Dual Wave Length Device for the Treatment of Onychomycosis
|
| 5/19/2008 |
NovaDel Announces European License Agreement for Ondansetron Oral Spray
|
| 5/12/2008 |
Argos Therapeutics Initiates Phase 2 Proof-of-Concept Trial for its Arcelis™ Personalized Immunotherapy Platform in HIV
|
| 5/12/2008 |
Arbios Receives Approval from the FDA to Initiate Pivotal Trial for SEPET™ Liver Assist Device
|
| 5/1/2008 |
Idera Pharmaceuticals Achieves Preclinical Milestone Under Collaboration with Merck & Co., Inc.
|
| 4/23/2008 |
Argos Therapeutics Secures $35.2 Million Series C Financing
|
| 4/22/2008 |
Cambria Pharmaceuticals Announces $5.4 Million Series A Financing
|
| 4/14/2008 |
TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanism-of-Action at AACR Annual Meeting
|
| 4/10/2008 |
Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
|
| 4/1/2008 |
SRU Biosystems Announces Introduction of Cartridge Reader Using BIND® Label-free Technology
|
| 3/31/2008 |
Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis™ Platform in HIV at Keystone Symposia
|
| 3/25/2008 |
SRU Biosystems Announces Introduction of BIND® 384/1536 TURBO Reader Using Label-free Technology
|